Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06822049 · ClinicalTrials.gov registry record · Phase 2
Remote vs. In-Person Study Evaluation (RISE) Trials: RISE Above Smoking (Trial 1)
A Phase 2 study of Remote vs. In-Person and Remote Visits, sponsored by State University of New York at Buffalo.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 200
- Enrollment target
- 2
- Study locations
NCT06822049: Recruiting Phase 2 study of Remote vs. In-Person and Remote Visits, sponsored by State University of New York at Buffalo.
NCT06822049 is a Phase 2 study of Remote vs. In-Person and Remote Visits that is actively recruiting participants, run by State University of New York at Buffalo. The registered enrollment target is 200 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (50% higher). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06822049, a Phase 2 study of Remote vs. In-Person and Remote Visits, is actively recruiting participants, sponsored by State University of New York at Buffalo.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 200 participants
- Enrollment target
- 2
- Study locations
Study Summary
The study will employ a randomized, parallel-group design with two-stage randomization. After an initial brief screen for basic eligibility, participants will be randomized (within site) to either Remote (R) or In-Person (IP) Intake Groups. During the Intake, detailed consent and eligibility assessment will be completed. Participants who are eligible at the Intake will be randomized (within site and Intake Group) to R or IP Treatment and Assessment Groups. Participants will be followed for 3 months.
Primary Outcome
Calculated from visit milestones. Of participants who were eligible on the Brief Screen, the percentage who who attend the (Remote vs. In-Person) Intake Visit, a major accrual bottleneck for in-person trials. Although pre-treatment participant loss from Intake to Clinic 1 is typically modest, we will also explore Intake to T/A Visit 1 (first dose of treatment) attrition and overall pre-treatment attrition (from Brief Screen to T/A Visit 1) for each group.
Conditions Studied
Interventions
- DRUG Combination Nicotine Replacement Therapy (patch and lozenge)
Study Locations (2)
New York
- University at Buffalo - Buffalo
Pennsylvania
- University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2025-03-10 |
| Est. Completion | 2027-02-28 |
| Phase | Phase 2 |
What NCT06822049 shows while recruiting
NCT06822049 is an interventional study that assigns participants to a tested intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (50% higher).
The record links to 3 conditions, with Remote vs. In-Person appearing as the primary indexed condition, and to 1 intervention - of which Combination Nicotine Replacement Therapy (patch and lozenge) is the first listed.
NCT06822049 reports a single indexed study location in New York, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT06822049 about?
NCT06822049 is a clinical study titled "Remote vs. In-Person Study Evaluation (RISE) Trials: RISE Above Smoking (Trial 1)". The study will employ a randomized, parallel-group design with two-stage randomization. After an initial brief screen for basic eligibility, participants will be randomized (within site) to either Remote (R) or In-Person (IP) Intake Groups. During the Intake, detailed consent and eligibility assessm...
What is the current status of trial NCT06822049?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 200 participants. The study started on 2025-03-10. Estimated completion is 2027-02-28.
What conditions does trial NCT06822049 study?
This clinical trial studies the following conditions: Remote vs. In-Person, Remote Visits, In-person Visits.
What interventions are being tested in trial NCT06822049?
The interventions under investigation include: Combination Nicotine Replacement Therapy (patch and lozenge) (DRUG).
Who is sponsoring clinical trial NCT06822049?
This trial is sponsored by State University of New York at Buffalo, which has 243 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06822049 being conducted?
This trial has 2 study locations across New York, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06822049's enrollment target sits among peer trials
200 304th of 2000 higher than 1,652 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- NCT00109174 · 200 participants · NA
MRS Measurement of Glutamate and GABA Metabolism in Brain
- NCT00177268 · 200 participants
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
- NCT00493688 · 200 participants
A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI